MERCK
20.12.2021 14:02:06 CET | Business Wire | Press release
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.
“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.
Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.
Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.
About Chord Therapeutics
Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. Chord is advancing its lead drug candidate, CRD1 (cladribine), for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and generalized myasthenia gravis (gMG). Chord Therapeutics was founded in 2014 and launched in October 2020 with Series A funding by its sole investor, Omega Funds, a leading international venture capital firm focused on delivering impactful medicines to patients.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
Elliptic Announces Circle’s Participation in Agentic Design Partner Program9.7.2026 14:15:00 CEST | Press release
Following investment from Circle Ventures, the corporate venture arm of Circle Elliptic, the global leader in digital asset intelligence, today announced that an affiliate of Circle Internet Group, Inc. (‘Circle’) (NYSE:CRCL) has joined its Agentic Design Partner Program, bringing together infrastructure providers, compliance teams, and technology leaders to help shape compliance solutions for autonomous, AI-driven financial activity. This momentum follows an investment from Circle Ventures, the corporate venture arm of Circle, and builds on a longstanding collaboration between the companies. Circle has been an Elliptic customer for multiple years and has expanded its use of Elliptic’s compliance capabilities across a range of digital asset initiatives. As stablecoins, tokenized assets, and AI-powered applications become increasingly integrated into financial services, new compliance challenges are emerging. Elliptic’s agentic compliance layer addresses these challenges by combining un
Russell Investments Announces New Long-Term Owners9.7.2026 14:00:00 CEST | Press release
An investor consortium led by B Capital and including CalPERS will provide long-term capital to expandRussell Investments’ client capabilities and accelerate innovation Russell Investments, the global investment solutions provider, today announced that an investor consortium (the “Investor Consortium”) led by B Capital, a global multi-stage investment firm, and including California Public Employees' Retirement System ("CalPERS"), has agreed to acquire the firm from TA Associates (“TA”) and Reverence Capital Partners (“RCP”). The transaction comes as Russell Investments marks over $416 billion in global assets under management (AUM) and has experienced more than 15% organic growth over the past two years. Russell Investments has been a trusted, independent partner to its clients for over 90 years. Its open-architecture model delivers portfolio solutions that source from the full landscape of the asset management industry across public and private markets. With a shared vision for the co
Esri and Global Partners Release HydroSHEDS v2 for the Americas9.7.2026 14:00:00 CEST | Press release
Next-Generation Hydrographic Framework Delivers Unprecedented Detail for Watershed and River Network Analysis Esri and its global partners have released HydroSHEDS v2, providing high-resolution hydrographic data for North, Central, and South America. Developed with World Wildlife Fund in the US, McGill University and Confluvio Consulting in Canada, and the German Aerospace Center (DLR), the initiative reflects global collaboration in hydrologic science and geospatial technology. HydroSHEDS v2 leverages TanDEM-X elevation data and Arc Hydro workflows to deliver more accurate drainage networks, watershed boundaries, and hydrologic connectivity. The datasets support applications such as flood risk assessments, climate resilience studies, systematic conservation planning, water resource management, and environmental decision-making. HydroSHEDS v2 datasets are available through ArcGIS Living Atlas, with additional global releases planned as part of a phased rollout. Esri has made HydroSHEDS
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom